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IMFERON-an iron dextran complex (Benger Laboratories)-has been widely
used as a therapy for anaemia. Laboratory testing of this drug indicated a
carcinogenic effect which discouraged its free use (Richmond, 1957, 1959, 1960;
Golberg et al., 1960; Golberg and Smith, 1960; Haddow and Horning, 1960;
Roe et al., 1964; Roe and Haddow, 1965). Newer easily assimilable iron com-
plexes have since then come on to the market (Lundin, 1961). Cipla Laboratories
put out a product named " Muscularon ", which is a solution ofiron and syntheti-
cally prepared polysaccharide ofmean molecular weight ofabout 20,000. The pH
of Muscularon is neutral and it is isotonic with plasma. This complex is highly
soluble and can be made up in the form of an aqueous solution for testing at
different concentrations. Each ampoule of 2 ml. contained 100 mg. of iron
hydroxide complex withpolymerised dextrose in 2% benzyl alcohol. This product
was taken up for laboratory testing (at the Company's request), and the results
are reported in this communication.
MATERIAL AND METHODS
Two strains ofmice, one inbred and the other a hybrid ofXVII x C57 (Black)
strains, were chosen as experimental animals. Males and females of these strains
between 10-13 weeks of age were used. Muscularon Batch No. 1010 and 1061
and Imferon Batch No. 3436 were utilised for test.
Three different doses (0.2 ml., 01 ml. and 0 05 ml. per injection) of the above
mentioned iron complexes were administered. Ten injections of each dose were
given at weekly intervals, either subcutaneously or intramuscularly. In all the
six groups injections were given alternately on the two sides of the animals. A
total of 254 mice (101 Swiss and 153 hybrid) were used in these tests.
The treated animals were kept under observations till they looked weak and
emaciated. When they were killed, the visceral organs, tumours when present,
and the sites of injections were fixed in 10% formalin and Bouin's fixative for
histological study. Routine H. and E. preparations of these tissues were ex-
amined. Gomori's method of the Prussian blue reaction for iron was carried out
on liver, kidney, spleen, tumours and sites ofinjection in selected animals.
RESULTS AND COMMENTS
Imferon, previously proved to be carcinogenic, was used as a positive control
for Muscularon. A solvent control (Benzyl alcohol) was not kept as its non-
carcinogenic action has already been reported (Hartwell, 1951). The untreated
control animals were kept under observation; however, as no spontaneous lesionsTESTING OF IRON COMPLEXES
of skin or muscle were observed in them, they are not included in the tabulated
data.
TABLE L.-Observations on Testing of Muscularon (Cipla Laboratories) and of
Imferon (Benger Laboratories)
Dose per
injection
(ml.)
MUSCULARON
0-2
J
Total No. of
mice (Strain)
and route of
administration
Mice survived over
No. 10 months of age
(1 T hA
26(S) IM 14 12
14(H) IM - 14
Remarks
Intolerable dose
- 3
0-1
23(S) IM 11 12
36(H) IM 12 24
22(H) SC 11 11
10(S) IM
0.05 22(H) SC
- 10
11 11
11* 10
91 16*
8 t7*
3
6 10*
* 2 Fibrosarcomas at 10 months
* 1 Fibrosarcoma at 21 months
$ 1 Lymphosarcoma at 22 months
* 1 Pleomorphic sarcoma at
27 months
t 2 Inflammatory reactions
* 1 Early fibrosarcoma at
25 months
8 6 1 2
10
12
6
8
5
12
6
10
6
7
6*
8
4
7
5
5
6
Intolerable dose
* 1 Fibrosarcoma at 24 months
12(H) SC 6 6 6 6
S = Swiss
H = Hybrid XVII X C57 (B1)
IM = Intramuscular injection
SC = Subcutaneous injection
From the observations given in Table I it appears that 0-2 ml. (10 mg. ofiron)
ofMuscularon and Imferon per injection is a high dose. The majority of animals
died between 2 to 7 months after the termination ofthe treatment. The massive
overloading with iron caused oedema of the subcutis and ulceration of the skin.
This dose was, therefore, not used for subcutaneous administration ofMuscularon.
The dose of 0-1 ml. per injection of Muscularon was tolerated well. Nearly
70% (57/81) of the animals survived over 10 months of age and the first tumour
was palpated five months after the last injection. Out of 23 Swiss mice (Table I)
receiving intramuscular injections, 21 (11 males and 10 females) survived over
10 months of age and two males from this group developed fibrosarcomas. The
tumour cells were loaded with iron deposits. From the group of 36 hybrid mice
treated in the same manner, 25 (9 males and 16 females) survived over 10 months.
One female developed fibrosarcoma at 21 months and one male developed lympho-
sarcoma at 22 months of age. When the same dose was administered sub-
cutaneously, out of 22 hybrid mice, 15 mice (8 males and 7 females) survived over
10 months of age. One of the females from these 15 animals developed a fibro-
sarcoma showing considerable pleomorphy. In 2 other females from the same
group, nodular growth was apparent at autopsy. The microscopic picture
IMFERON
0*2 }
14(H) IM
10(H) SC
24(S) IM
12(H) IM
18(S) SC
II(H) SC
0-1 }
0 05
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revealed few giant cells amongst the brownish pigment laden cells. When the
same sections were tested for the presence of iron, these areas gave a heavy
prussian blue colouration. There was abizarre picture ofnormallookingfibrocytic
cells suggestive of an inflammatory reaction.
From the group of 65 mice treated with a dose of 0-1 ml. ofImferon per injec-
tion 48 (74%) survived over 10 months of age. When given intramuscularly out
of 12 hybrid mice (6 males and 6 females) 11 survived over 10 months and one
male developed fibrosarcoma. The heavy deposits of iron could be well located
even withH. and E. staining. The presence of iron in the tumour was confirmed
by the prussian blue reaction. The liver ofthe same animal was positive for iron,
but the kidney was free of iron. This solitary tumour induced by Imferon was
transplanted subcutaneously into six hybrid mice. Three ofthe 6 mice developed
tumours within 2 months. Other treated animals from both the groups failed to
show any abnormality except an overload of iron.
Summarizing the findings on a dose of 0.1 ml. per injection, Muscularon
induced 4 fibrosarcomas and one lymphosarcoma in two strains of mice. All the
animals had received 50 mg. of iron as a total dose. One of the tumours was
tested for its transplantability in homologous hosts. All 6 mice used for sub-
cutaneous transplantation failed to take the tumour. With Imferon one trans-
plantable tumour was obtained with this dose.
Out of 16 survivors from the group of 22 mice receiving the dose of 0 05 ml.
per injection early tumour was seen in hybrid female mouse nearly 20 months after
the treatment. Microscopically, the tumour had anirregular cellular organisation,
with spindle cells which showed a good number of mitotic figures. Some of the
spindle cells proliferating in the subcutis suggested the formation of a presarco-
matous lesion.
Of these two iron complexes, Imferon induced only one tumour out of 77
treated mice. With Muscularon 4/80 hybrid mice and 2/33 Swiss mice developed
sarcomas, making atotal of6tumours outof113 animals. Thetumoursdeveloped
between 16 to 22 months after the treatment in the case of hybrid mice and at 5
months in Swiss mice.
DISCUSSION
Muscularon was supplied by Cipla Laboratories (India) to test its carcino-
genicity on experimental animals. It differs from Imferon in having the poly-
saccharide that is obtainedbypolymerization ofdextrose as against dextran which
is a fermentation product of sugars. Secondly, Muscularon is stable to heat and
change ofpH, while Imferon is unstable. It was therefore expected that Muscu-
laron would fail to give any tumours.
Although these two compounds are with different complex formation the
overload ofiron was significantly seen in all the treated animals. The presence of
iron was not only seen at the site ofinjection but also in the kidney cortex and the
centrilobular and periportal areas of the liver.
With Imferon, one transplantable fibrosarcoma developed in treated animals,
while Muscularon induced six tumours. The tumour yield, though poor, (6/153
treated mice) was sufficient to warrant the carcinogenic action of this compound.
The absorption ofiron from the site of injection is very slow, which suggests that
the haemopoietic system is unable to pick up the iron given in this form. Efforts
should be directed to synthesizing an injectable iron which will minimize the localTESTING OF IRON COMPLEXES 451
effects through rapid absorption and mobilisation from the site. It would perhaps
help better understanding of the effects of iron injections if experiments were
carried out on anaemic animals.
SUMMARY
1. Muscularon and Imferon, two iron complexes, were tested for their carcino-
genicity on mice by two different routes: (i) intramuscular and (ii) subcutaneous
injections. Ten injections of three different doses were used to find out the most
tolerable non-toxic dose without any carcinogenic effect.
2. Imferon, which is known to induce fibrosarcoma, was used for comparing
the results obtained with Muscularon.
3. Out of 101 mice treated with Imferon one hybrid mouse developed a trans-
plantable fibrosarcoma.
4. With Muscularon, administered by two different routes, six tumours were
obtained in 153 mice.
5. The use ofiron complexes as atherapeutic drugin anaemias ofiron deficiency
type needs consideration as the iron gets localised at the site of injection. It
therefore acts as a foreign body and phagocytosis is more common.
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